Zobrazeno 1 - 10
of 32
pro vyhledávání: '"B Montoro-Ronsano"'
Autor:
A Pau Parra, B Montoro Ronsano, P González Moreno, D Anguita Domingo, J Vima Bofarull, MQ Gorgas Torner, D Campany Herrero
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
J. B. Montoro-Ronsano, R. P. Bury-Macias, I. Agraz-Pamplona, M. Larrosa-Garcia, D. Serón-Micas
Publikováno v:
European Journal of Clinical Pharmacology
Autor:
C Varon-Galcera, K Mendoza-Paredes, M Hernandez-Gonzalez, MQ Gorgas-Torner, B Montoro-Ronsano, M. Larrosa-Garcia, M Martinez-Gallo, I. Agraz-Pamplona, R. P. Bury-Macias
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Biosimilar drugs should have proven clinical efficacy comparable with the referring brand to obtain authorisation from medicine regulatory agencies. Nevertheless, the effectiveness and safety of off-label uses are not always
Publikováno v:
Revista espanola de medicina nuclear e imagen molecular. 39(4)
The aim was to analyze the cost-effectiveness ratio (CER) of stress electrocardiogram (ES) and stress myocardial perfusion imaging (SPECT-MPI) according to coronary revascularization (CR) therapy, cardiac events (CE) and total mortality (TM).A total
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Maria Roch-Santed, Juan C. Juárez-Giménez, David Brandariz-Núñez, Celia González-Guerrero, Jose B. Montoro-Ronsano, Lourdes Pastó-Cardona, Lucas Rivera-Sánchez, Toni Lozano-Andreu
Publikováno v:
Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 28(1)
The aim of the study was to assess the influence of fibrinogen concentrate on survival when it is used in trauma patients with life-threatening hemorrhagic disorders. Secondly, to evaluate when the fibrinogen concentrate administration maximizes its
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J B Montoro-Ronsano, C Ibáñez
Publikováno v:
Current Pharmaceutical Biotechnology. 4:239-247
Intravenous immunoglobulins (IVIg) have been used as a substitutive treatment for primary and secondary humoral immune deficiencies for several decades. In the meantime, increased experience has been acquired with IVIg in the management of other infl
Autor:
S R, Leal-Noval, M, Muñoz, M, Asuero, E, Contreras, J A, García-Erce, J V, Llau, V, Moral, J A, Páramo, M, Quintana, M, Basora, F J, Bautista-Paloma, E, Bisbe, J L, Bóveda, A, Castillo-Muñoz, M J, Colomina, C, Fernández, E, Fernández-Mondéjar, C, Ferrándiz, A, García de Lorenzo, C, Gomar, A, Gómez-Luque, M, Izuel, V, Jiménez-Yuste, E, López-Briz, M L, López-Fernández, J A, Martín-Conde, B, Montoro-Ronsano, C, Paniagua, J A, Romero-Garrido, J C, Ruiz, R, Salinas-Argente, C, Sánchez, P, Torrabadella, V, Arellano, A, Candela, J A, Fernández, E, Fernández-Hinojosa, A, Puppo
Publikováno v:
Medicina intensiva. 37(4)
Since allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to ABT (AABT) have emerged, though there is great variability in their indications and appropriate use. This variability results from the interaction of a number of facto
Autor:
J B, Montoro Ronsano
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 30(1)